[Modification of thrombocyte function in diagnostic and therapeutic interventions in cardiology].
In patients with coronary heart disease platelet activity may be pathologically increased. Administration of platelet inhibitor drugs is an established treatment principle. The interactions between platelet activation, platelet inhibitor drugs like acetylsalicylic acid (ASA) or molsidomine and the endogenous fibrinolysis were studied in three trials. Platelet aggregation and thromboxane synthesis are dose- dependently inhibited after oral intake of ASA (0, 10, 30, 100 or 500 mg/d) Additional intake of the antianginal agent and nitric oxide donator Molsidomine (8 mg) results in a synergistic platelet inhibitor effect characterized by a significantly delayed aggregation response. In a group of patients with coronary artery stenoses platelet activity was markedly enhanced, when compared to healthy individuals. During physical exercise platelet activity was even further enhanced and plasma t-PA-activity was increased by a factor of 2.2. The stimulation of the endogenous fibrinolytic system was markedly reduced when compared to healthy subjects. Following successful coronary angioplasty 393 patients were randomized to receive either molsidomine (2 x 8 mg/d) or ASA (1 x 500 mg/d) plus nifedipine (3 x 20 mg/d). Coronary angiography performed after the 6 month treatment period revealed a restenosis rate of 29% in the molsidomine group and of 33% in patients treated with ASA + nifedipine. This difference was not statistically significant.
Darius
H
H
II. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz.
Beisiegel
B
B
Erbel
R
R
Rupprecht
H J
HJ
Hafner
G
G
Pop
T
T
Treese
N
N
Meyer
J
J
D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000008:administration & dosage*; D003327:Coronary Disease / Q000097:blood* / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005080:Exercise Test; D005342:Fibrinolysis / Q000187:drug effects / Q000502:physiology; D005500:Follow-Up Studies; D006801:Humans; D008981:Molsidomine / Q000008:administration & dosage*; D015539:Platelet Activation / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D012008:Recurrence; D013931:Thromboxanes / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D010975:Platelet Aggregation Inhibitors; D013931:Thromboxanes; D008981:Molsidomine; D010959:Tissue Plasminogen Activator; D001241:Aspirin
Beeinflussung der Thrombozytenfunktion bei diagnostischen und therapeutischen Eingriffen in der Kardiologie.